India's Weight Loss Drug Boom: Miracle Cure or Risky Fad?

India faces a growing epidemic of diabetes and obesity, with weight loss drugs seeing unprecedented demand. Mounjaro, a popular injectable medication for diabetes and obesity, has become India's top-selling drug since its approval. Drug companies like Eli Lilly and Novo Nordisk are actively participating in this expanding market.

While hailed by many as a necessity for public health, medical professionals express significant concerns about the unregulated boom. Experts like bariatric surgeon Mohit Bhandari warn of serious potential side effects, including muscle loss, pancreatitis, and even blindness, urging strict government regulation on prescription and distribution.

The market is expected to become a major global hub for these drugs, especially as patents expire, allowing for cheaper domestic versions. However, physicians stress that these medications are not a magic solution and must be complemented by lifestyle changes, nutrition education, and exercise to truly combat India's health crisis.